Vaccine

--Clover launches AdimFlu-S (QIS) in mainland China, the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older --  --Second commercialized product strengthens Clover’s leading…

KUALA LUMPUR, Malaysia, Sept. 05, 2023 (GLOBE NEWSWIRE) -- The Global HPV Consortium, a worldwide public and private collaboration focused on accelerating prevention of Human Papillomavirus (HPV) and eliminating cervical cancer, launched…

ABNCoV2 and the comparator vaccine demonstrated a reduced level of neutralizing antibodies against a circulating variant (Omicron XBB.1.5) in Phase 3 study.cVLP platform has proven its ability to induce strong and lasting immunity against…

Saint-Herblain (France), August 29, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has completed screening validation of the Company’s regulatory application for…

Phase 3 study failed to meet one of the success criteria of the primary objectiveRSV program to be discontinued COPENHAGEN, Denmark, July 22, 2023 – Bavarian Nordic A/S (OMX: BAVA) today announced that its Phase 3 clinical trial of…

Saint-Herblain (France), June 13, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that the Company’s pivotal Phase 3 data for its single-shot chikungunya vaccine candidate, VLA1553, have…

WASHINGTON, June 06, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the 30th Albert B. Sabin Gold Medal Award to Thomas P. Monath, MD, and its Rising Star Award to Sangwe Clovis Nchinjoh, MD, MPH, in a ceremony at…

CEPI to initially provide up to US$1.6 million to aVaxziPen to advance development of needle-free vaccine technology aVaxziPen’s innovative vaccine delivery platform aims to improve access to vaccines by removing the need for…

The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerabilityPositive clinical responses were reported in 8 out of 12 EVX-01 treated patientsHigh-quality neoantigens, predicted by AI…

Saint-Herblain (France), May 30, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the filing of a regulatory application with Health Canada for marketing approval of the Company’s…